EXTENDED REPORT

Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort

Camille Roubille,1,2 Nathalie Rincheval,1,3 Maxime Dougdos,4,5 René-Marc Flipo,6 Jean-Pierre Daurès,3 Bernard Combe1

ABSTRACT

Objective  To explore the 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA).

Methods  We examined data for 602 patients with RA from the early arthritis Etude et Suivi des POLYarthrites Indifférenciées Récentes (ESPOIR) cohort (<6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years IQR 0.038–7.65). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture.

Results  Among the 602 patients with RA (476 women (79%), mean age 48±12 years), 386 with GC (64.1%) received low-dose prednisone (mean 3.1±2.9 mg/day for the entire follow-up): 263 started GC during the first 6 months (68%), and the mean duration of total GC treatment was 1057±876 days. As compared with patients without GC (216 (35.9%)), those with GC showed greater use of non-steroidal anti-inflammatory drugs, synthetic and biological disease-modifying antirheumatic drugs and had more active disease disability, higher C reactive protein and anticitrullinated protein antibody levels. Among 65 events (7 deaths, 14 cardiovascular diseases, 19 severe infections and 25 fractures), 44 and 21 occurred in patients with and without GC (p=0.520). Infections were more frequent, although not significantly, in patients with than without GC (p=0.09). On weighted Cox proportional-hazards analysis, with use of propensity score and inverse-probability-of-treatment weighting, and including age, gender, history of hypertension and GC treatment, outcomes did not differ with and without GC (p=0.520; HR=0.889; 95% CI 0.620 to 1.273).

Conclusions  This 7-year analysis of the ESPOIR cohort supports the good safety profile of very low-dose GC for early active RA.

INTRODUCTION

Glucocorticoids (GC) are commonly prescribed for patients with rheumatoid arthritis (RA), especially in the early stages of the disease. However, beyond their symptomatic and structural benefits,1 the risk/benefit ratio of GC remains controversial,2 with concerns about the tolerability profile. GC adverse events have been reported to be time-dependent and dose-dependent, so international guidelines support the use of the lowest dose for the shortest duration.3 4 GC use in RA remains controversial, mostly because of concerns about long-term safety outcomes, including cardiovascular disease (CVD), infection, diabetes, weight gain, osteoporosis and fracture.5 Nevertheless, despite the fear of adverse events, GC are widely used in RA, especially in early active diseases, with variable dosage and duration. For instance, in the UK, 50% of patients with incident RA were reported to receive GC in primary care, with more than 50% receiving doses >10 mg/day.6 In the German Course And Prognosis of Early Arthritis (CAPEA) inception cohort, 77% of patients initially received oral GC, 20% receiving low-dose GC (<7.5 mg/day) and 35% high-dose GC (≥20 mg/day).7 By contrast, in the Canadian CATCH cohort, only 42% of patients started on GC; 48% received oral GC (≤10 mg/day) and 38% intra-articular or intramuscular GC.8 In another inception cohort from Latin America, 64% of early patients with RA took GC (80% ≤10 mg/day of prednisone).9 Notably, despite the longstanding use of GC for daily RA management, few strong evidence-based safety data are available.10 11 Therefore, the safety of GC remains on the research agenda, especially the tolerability profile in early RA.

In the Etude et Suivi des POLYarthrites Indifférenciées Récentes (ESPOIR) cohort (see online supplementary method 1),12 13 more than half of patients received GC at least once over 5 years after inclusion, especially during the first 6 months of follow-up.14 Thus, investigation of consecutive events occurring after GC initiation in this cohort may give insight into the long-term safety profile of GC use in a real-life setting.

Here, we aimed to explore the 7-year tolerability profile of GC for patients with recent-onset RA (ESPOIR cohort) by determining the association between GC use and major safety events, including death, CVD, severe infection and fracture.

PATIENTS AND METHODS

Study design and setting

The ESPOIR cohort is a French prospective multicentre observational cohort sponsored by the French Society of Rheumatology that included patients (aged 18–70 years) with early arthritis from 14 rheumatology centres in France. To be included, patients had to have inflammatory arthritis in at least two swollen joints lasting from 6 weeks to 6 months, with the potential to develop
into RA, and be naïve to disease-modifying antirheumatic drugs (DMARDs) and GC therapy. The exclusion criterion was early inflammatory joint disease meeting criteria for a definite diagnosis other than RA or exhibiting features that ruled out progression to RA. The ESPOIR cohort included 813 patients between 2002 and 2005. The objective, design and characteristics of the cohort were previously described (see online supplementary method 1). The database for the present study was locked in 2013 at the 7-year time point. The protocol of the ESPOIR cohort was approved by the ethics committee of Montpellier, France (no. 020307). All patients gave their signed informed consent before inclusion.

Patients and GC use
Among the 813 patients included, we selected the 712 who fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism criteria for RA over the 7 years of follow-up (figure 1). We excluded patients with a history of CVD (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection or fracture because we anticipated that such patients might have had a different profile for GC prescription (expected to less frequently receive a prescription from rheumatologists) and risk of related side effects (likely greater).

We also excluded patients with missing data for GC treatment and those not followed-up to 1 year (figure 1), to provide sufficient monitoring data and a sufficient duration of follow-up to ensure that the impact of GC was a true effect and not due to chance in a short observation period (see online supplementary method 2).

Hence, we examined data for 602 patients with an RA diagnosis. To consider the group of patients with a history of CVD, severe infections and fractures, we also analysed data for 657 patients comprising the 602 included patients and the 55 patients with such a history, and no missing data (figure 1).

The included patients were then classified into two groups by whether or not they received GC at least once (with or without GC) over the 7 years of follow-up. The group with GC comprised patients who received systemic GC treatment (oral, intramuscular or intravenous) at least once between inclusion and the end of follow-up. The group without GC comprised patients who never took GC between inclusion and the end of follow-up. Patients who received only intra-articular injections of GC or inhaled GC were included in the group without GC, given the minimal systemic spreading.

GC use was defined as use (yes or no) when the first safety event occurred. Doses were calculated as prednisone-equivalent based on accepted standards. For each patient with GC treatment, the mean dosage of GC was calculated by dividing the total quantity of GC by the duration of the entire follow-up.

Outcomes and variables
The primary outcome was a composite of new-onset safety events including all-cause mortality, CVD (myocardial
ischaemia, cerebrovascular accident and heart failure), severe infection and fracture. Only new-onset events reported were considered so as to ensure the relevance of the association with GC treatment. We selected as covariates some factors known to affect cardiovascular, infection and fracture risks: age, gender, body mass index (BMI), diabetes, hypertension, smoking status, hypercholesterolaemia and use of non-steroidal anti-inflammatory drugs (NSAIDs). A variable named ‘cardiovascular risk’ was created to account for the presence of at least one cardiovascular risk factor among hypertension, hypercholesterolaemia, BMI >30 kg/m², diabetes and smoking. All all-cause deaths were considered. CVD included myocardial infarction, acute coronary syndrome, angina pectoris, stroke (ischaemic or haemorrhagic) and heart failure. Severe infection was defined as requiring hospitalisation or intravenous antibiotics. Outcomes were recorded in the cohort file.

**Statistical analyses**

Descriptive statistics are presented as mean±SD or number (%) where appropriate. The non-parametric Mann-Whitney U test was used to compare the distribution of continuous variables and \( \chi^2 \) test (or Fisher’s exact test) to test the association of categorical variables. Continuous variables were transformed into categorical variables with the median or a predetermined threshold. The \( p \) values <0.05 were considered significant and all statistical tests were two-sided. The composite primary outcome was compared by \( \chi^2 \) test (or Fisher’s exact test) on univariate analysis. Thereafter, Cox proportional-hazards regression was used to assess the association between GC treatment and outcome, estimating HRs and 95% CIs. To reduce the impact of treatment selection bias and potential confounding, the outcome, estimating HRs and 95% CIs. To reduce the impact of treatment selection bias and potential confounding, the weighted Cox proportional-hazards model was used with inverse-probability of treatment weighting (IPTW).\(^{18}\) With this method, weights for patients who had and patients who had not received GC treatment were the inverse of ‘propensity score’ (PS) and the inverse of ‘1–PS’, respectively. To account for potential confounding by indication, where patients with more severe disease would be more likely to receive GC, we used a PS. The PS is defined as the predicted patient’s probability of receiving GC, conditional on a set of observed baseline covariates. The PS was estimated by multiple logistic-regression analysis. Two sets of observed baseline covariates were included in the PS model (see online supplementary figures S1 and S2).\(^{19}\) The first set of covariates, selected by using the log-rank test, was related to the outcome and the second set, selected using \( \chi^2 \) test, was related to GC treatment (see online supplementary figures S1 and S2). Of note, all Disease Activity Score in 28 joints (DAS-28) C reactive protein (CRP) levels were not significant, therefore we preferred including each component of the DAS-28 CRP score separately. For both long-rank and \( \chi^2 \) tests, the level of significance was set at \( p<0.15 \). In addition, we used three procedures for selecting variables (forward, backward and stepwise) to obtain the most appropriate logistic-regression equation. All procedures led to the same model. The baseline covariates retained in the final PS regression model were: anticitrullinated protein antibodies (ACPA), diabetes, Health Assessment Questionnaire (HAQ) score, van der Heijde-modified Sharp score (mSHS), cardiovascular risk and patient’s overall assessment using visual analogue scale (see online supplementary figure S1). The PS was then included in the Cox proportional-hazards model with the baseline covariates that were significant at 15% on the log-rank test and not already included in the PS model: age, gender, history of hypertension, in addition to GC treatment (yes or no).

In the analysis of the 657 patients, comprising the 602 patients without a history and the 55 patients with a history and sufficient data, the methodology was similar. The two sets of covariates included in the PS model were the same as in the principal analysis, with, in addition, the covariate history of CVD, severe infection or fracture. The baseline covariates retained in the PS regression model for this analysis were the same, except for mSHS (see online supplementary figure S2). The PS was then included in the Cox proportional-hazards model with age, gender, history of hypertension, BMI >30 kg/m², CRP, rheumatoid factor (RF), history of CVD, severe infection or fracture, in addition to GC treatment (yes or no). Furthermore, the original studied population could be considered different subgroups on the basis of the cumulative GC dose and total duration of GC treatment over 7 years. These two variables were transformed into a four-level categorical variable by quartiles. First, the log-rank test was used to evaluate the effect of the two covariates with time to event data. Moreover, to adjust for such subgroup differences, an extension of the standard Cox model was used to create two stratified Cox models based on the categorical variable levels. \( p \) Value <0.05 was considered to be statistically significant and all statistical tests were two-sided. All statistical analyses involved use of SAS V9.3 (SAS Institute, Cary, North Carolina, USA).

**RESULTS**

The study population comprised 602 patients with RA (476 women (79%), mean age 48±12 years; table 1). Mean duration of follow-up was 5.98±1.84 years (median 7 years IQR (0.038–7.65)). Baseline characteristics of the entire sample are shown in table 1: 91% had moderate to high disease activity, and almost 45% were ACPA-positive. A total of 386 (64.1%) received GC during follow-up and 216 never received GC (35.9%). Patients with GC mainly received low-dose prednisone during follow-up (mean 3.1±2.9 mg/day, median 2.4 mg/day (IQR 0.7–5) for the entire follow-up); over half started GC during the first 6 months (n=263, 68.1%). Among the 386 patients who received GC, 73 (19%) received GC for ≤6 months, and 185 (almost 50%) for 2 years (see online supplementary table S1); 69 patients received GC for up to 6 years (18%). The mean duration of total GC treatment was 1057±876 days (median 803 days (IQR 267–1829)) and 280 (72.5%) received GC continuously for longer than 6 months. Six patients received only intravenous or intramuscular GC. Active disease was greater with than without GC, with significantly higher DAS-28-CRP level and HAQ score, as reflected by a greater consumption of DMARDs, biological agents and NSAIDs and higher CRP levels and ACPA titres (table 1).

**Effect of GC exposure: composite of death, CVD, severe infection and fracture**

A total of 65 events were reported in the entire population: 7 deaths, 14 CVD, 19 severe infections and 25 fractures (table 2).

Deaths occurred between years 4 and 7 and were caused by cancer or malignant blood diseases (n=4), salmonellosis (n=1), ruptured aortic aneurysm (n=1) or unknown cause (n=1).

Among these 65 events, 44 (11.4%) and 21 (9.7%) occurred in patients with and without GC (\( p=0.520 \) (table 2). The number of infections was greater, although not significantly, in patients with than without GC (\( p=0.09 \)).

When we considered patients with events (n=65) and compared patients with and without GC by DAS-28-CRP those with GC and moderate to high disease activity (DAS-28-CRP score...
### Clinical and epidemiological research

#### Table 1 Baseline demographic, clinical, biological and radiographic characteristics of the study population from the ESPOIR cohort (n=602) and those without and with GC

<table>
<thead>
<tr>
<th></th>
<th>Total study population (n=602)</th>
<th>Without GC (n=216)</th>
<th>With GC (n=386)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>602 48±12</td>
<td>48.9±11.8</td>
<td>47.5±12.2</td>
<td>0.210</td>
</tr>
<tr>
<td><strong>Female</strong></td>
<td>602 476 (79%)</td>
<td>176 (81.5%)</td>
<td>300 (77.7%)</td>
<td>0.277†</td>
</tr>
<tr>
<td><strong>BMI, kg/m²</strong></td>
<td>600 25±4.6</td>
<td>24.9±4.6</td>
<td>25.2±4.6</td>
<td>0.456</td>
</tr>
<tr>
<td><strong>BMI &gt;30 kg/m²</strong></td>
<td>602 83 (13.8%)</td>
<td>28 (13%)</td>
<td>55 (14.3%)</td>
<td>0.643†</td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td>602 19 (3.2%)</td>
<td>12 (5.6%)</td>
<td>7 (1.8%)</td>
<td>0.012†</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>602 98 (16.3%)</td>
<td>34 (15.7%)</td>
<td>64 (16.6%)</td>
<td>0.789†</td>
</tr>
<tr>
<td><strong>Hypercholesterolemia</strong></td>
<td>602 84 (14%)</td>
<td>28 (13%)</td>
<td>56 (14.5%)</td>
<td>0.600†</td>
</tr>
<tr>
<td><strong>Smokers</strong></td>
<td>602 291 (48.3%)</td>
<td>90 (41.7%)</td>
<td>201 (52.1%)</td>
<td>0.014†</td>
</tr>
<tr>
<td><strong>Hypertension or hypercholesterolemia or diabetes or BMI &gt;30 kg/m² or smoker</strong></td>
<td>602 401 (66.6%)</td>
<td>133 (61.6%)</td>
<td>268 (69.4%)</td>
<td>0.050†</td>
</tr>
<tr>
<td><strong>At least one DMARD treatment from baseline to 7 years</strong></td>
<td>567 541 (95%)</td>
<td>178 (93.2%)</td>
<td>363 (96.5%)</td>
<td>&lt;0.0001†</td>
</tr>
<tr>
<td><strong>At least one biological agent from baseline to 7 years</strong></td>
<td>602 164 (27%)</td>
<td>37 (17.1%)</td>
<td>127 (32.9%)</td>
<td>&lt;0.0001†</td>
</tr>
<tr>
<td><strong>Consumption of NSAIDs</strong></td>
<td>602 541 (89.9%)</td>
<td>183 (84.7%)</td>
<td>358 (92.7%)</td>
<td>0.002†</td>
</tr>
<tr>
<td><strong>DAS-28-CRP score</strong></td>
<td>600 4.8±1.2</td>
<td>4.4±1.1</td>
<td>5.0±1.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>CRP level (mg/L)</strong></td>
<td>602 20.2±33.9</td>
<td>13.2±22.1</td>
<td>24.1±38.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>CRP level &gt;10 mg/L</strong></td>
<td>602 274 (45.5%)</td>
<td>76 (35.2%)</td>
<td>198 (51.3%)</td>
<td>0.0001†</td>
</tr>
<tr>
<td><strong>RF (IU/mL)</strong></td>
<td>602 122.2±445.7</td>
<td>118.7±499.6</td>
<td>124.3±1631.8</td>
<td>0.111</td>
</tr>
<tr>
<td><strong>ACPA titres (IU/mL)</strong></td>
<td>602 555.7±1577.2</td>
<td>118.7±499.6</td>
<td>124.3±1631.8</td>
<td>0.0004†</td>
</tr>
<tr>
<td><strong>Hypercholesterolemia</strong></td>
<td>602 84 (14%)</td>
<td>28 (13%)</td>
<td>56 (14.5%)</td>
<td>0.600†</td>
</tr>
<tr>
<td><strong>Typical erosion</strong></td>
<td>571 153 (26.8%)</td>
<td>56 (27.7%)</td>
<td>97 (26.3%)</td>
<td>0.711†</td>
</tr>
<tr>
<td><strong>mSHS score</strong></td>
<td>574 5.4±7.8</td>
<td>6.0±8.4</td>
<td>5.1±7.4</td>
<td>0.090</td>
</tr>
</tbody>
</table>

Data are no. (%) or mean±SD. Bold is related to significant p-Values.

* p Values were assessed by Mann-Whitney U test.

† p Values were assessed by χ² test (or Fisher’s exact test).

ACPA, anticitrullinated protein antibodies; BMI, body mass index; CRP, C reactive protein; DAS-28-CRP, Disease Activity Score in 28 joints, with C reactive protein level; DMARD, disease-modifying antirheumatic drug; ESPOIR, Etude et Suivi des POlyarthrites Indifférenciées Récentes; GC, glucocorticoids; HAQ, Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; mSHS, van der Heijde-modified Sharp score.

>3.2) experienced significantly more events than those without GC (p=0.006). On weighted Cox proportional-hazards analysis (IPTW) (see online supplementary figure S1) including age, gender, history of hypertension and GC treatment, the composite outcome did not differ with and without GC (p=0.520; HR=0.889; 95% CI 0.620 to 1.273). The covariates with significant effect on the composite outcome were age (p=0.02; HR=1.636; 95% CI 1.085 to 2.467) and gender (p=0.003; HR=1.809; 95% CI 1.224 to 2.674).

In the analysis of the 657 patients including those with a history, the Cox IPTW analysis (see online supplementary figure S2) included age, gender, history of hypertension, history of CVD or fractures or severe infections, RF, CRP level, BMI >30 kg/m² and GC treatment. Again, the composite outcome did not differ with and without GC (p=0.767, HR=0.951; 95% CI 0.684 to 1.323).

Finally, regarding the four-level categorical variable representing cumulative dose and duration of GC treatment, neither the cumulative dose nor duration of GC treatment had an effect on survival (log-rank test, p=0.79 and p=0.57). Also, with two stratified Cox models used to assess the association between the covariates age, gender and history of hypertension and the composite outcome, while controlling for the four-level categorical variable, the results were similar to those with the initial Cox model (see online supplementary figure S3 and table S2).

**DISCUSSION**

In a cohort of very early RA from a real-life setting monitored for 7 years, we investigated the association between exposure to GC treatment and classical major safety events related to GC (death, CVD, severe infection, fracture). This 7-year data analysis of the ESPOIR cohort did not show any significant difference between patients with RA with and without GC treatment in terms of major safety events. Most of the patients who received GC therapy started GC during the first 6 months and received low-dose therapy. These results support the good safety profile of low-dose GC therapy for early RA and agree with the recent work by Strehl et al.20

GC are considered a bridging therapy, with short-term symptomatic21 22 and structural effects. However, the GC risk/benefit balance has little evidence base, with most recent data provided by observational studies. These studies provide the opportunity to explore the real-life tolerability profile of GC, with doses and duration commonly used in daily practice, but often present bias.

---


---
such as confounding by indication. As well as the evidence from randomised clinical trials is scarce. The GC tolerability profile has been reported to depend both on the duration of exposure and dose. Indeed, in addition to a better tolerability profile of a low-dose than high-dose regimen, long-term use of low-dose GC has been associated with increased mortality as compared with shorter exposures. Most notably, two recent studies suggested a dose-dependent increase in mortality in RA; del Rincón et al. revealed a daily threshold dose of 8 mg at which all-cause mortality increased with GC dose (adjusted HR=1.78; 95% CI 1.22 to 2.60), and in the German register Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT), use of GC >5 mg/day was associated with increased mortality risk, independent of RA activity. Moreover, a 10-year follow-up study examined cardiovascular events and deaths in early patients with RA with no history of CVD who were included in a recent open-label randomised trial of low-dose prednisolone (7.5 mg/day) over the first 2 years of early RA Better Anti-Rheumatic Pharmacotherapy (BARFOT+): low-dose prednisolone use was associated with increased incidence of cerebrovascular events and, although not significant, increased mortality. Long-term follow-up of Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA II) patients with early RA who received prednisone at 10 mg/day for at least 2 years revealed increased cardiovascular risk and, although not significant, increased mortality. In our study, most of the patients who took GC received low-dose GC, <5 mg/day (mean dosage during the entire follow-up 3.1±2.9 mg/day), for which the literature supports an acceptable safety profile.

Cardiovascular tolerance of GC remains controversial. In one meta-analysis of observational studies, GC usage was associated with increased risk of all cardiovascular events (relative risk=1.47; 95% CI 1.34 to 1.60), including myocardial infarction, heart failure and stroke. In another systematic literature review, low-dose GC (<10 mg/day) was associated with major cardiovascular events in four of six studies. GC therapy has been associated with increased risk of severe infections. One systematic review noted the paucity of data on the association between low-dose GC (<10 mg/day prednisone) and risk of infection. In one recent study evaluating patients with RA aged >65 years, the risk of serious infection was increased 30%, 46% or 100% with 5 mg prednisolone used continuously for the last 3 or 6 months or 3 years, respectively, as compared with no use. The increased risk of severe infection was also proportional to the cumulative dosage over 2–3 years.

Potential limitations of the present study are those inherent to observational studies, with potential confounders that could not be taken into account. Moreover, as in many cohort studies, the data are mostly declarative. The events and comorbid diseases were reported by patients, and a potential recall bias cannot be excluded. HAQ and disease activity variables that were selected by the logistic regression analysis and included in the PS were baseline variables, which could also be considered a limitation, because the relationship between GC-related events and disease activity evolution over time could not be evaluated. Using a composite end point is controversial, mostly because it may emphasise each patient’s first outcome. Nevertheless, GC toxicity is multifaceted and this way of assessing the most important adverse events may help identify the net effect of GC. We also decided to use a composite outcome including the four most relevant adverse events related to GC treatment, mainly to increase the number of events and to cover the four most worrisome adverse effects of GC therapy defined by a panel of rheumatologists. Moreover, we could not perform a dose-response analysis because of the low doses the patients received. Finally, the relatively small number of incident events might have implied relatively low power.

The present study has many strengths. First, the ESPOIR cohort offered a unique opportunity to explore the long-term impact of GC in very early RA, in a real-life scenario. Importantly, all participants who received GC started treatment after entering the cohort, and only incident safety events were considered. To our knowledge, this is the first cohort study specifically designed to assess (among other data) GC adverse effects and to report the long-term tolerability profile of GC use in early RA. Second, the present 7-year duration of follow-up provides a sufficient period of observation to ensure a true association between GC therapy and adverse effects related to long-term treatment. Third, the ESPOIR cohort has inherent qualities, including the prospective independent collection of data and low rate of missing data and dropout.

Finally, using a PS in this study limited the indication bias, thus reinforcing the association between GC and long-term adverse events. Indeed, several factors such as RA disease activity and comorbidities or history may have an impact on GC prescription. For instance, in one recent observational study, the association between GC use and increased incidence of CVD was negated after adjustment for disease activity and severity, which suggests an effect confounded by indication due to high disease activity. The propensity for prescribing GC is important to consider when evaluating the association between GC use and related outcomes, given that patients with RA with more active disease might have more likely received GC, and conversely, those with history of CVD or severe infections or fractures might have less frequently received GC. Therefore, using a PS allowed for adjusting of patterns that are difficult to fully account for by adjusting for only general and RA-related characteristics in regression modelling. In the ESPOIR cohort, several characteristics differed between patients with and without GC, which highlights the value of using the PS in evaluating the relationship between GC use and outcomes.

| Table 2 | Primary outcome at 7 years (death or cardiovascular disease or severe infection or fracture) in the total sample and patients with and without GC |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | Total study population (n=602) | Without GC (n=216) | With GC (n=386) | p Value* |
| Primary outcome             | 65 (10.8%)                   | 21 (9.7%)              | 44 (11.4%)       | 0.520 |
| Death                       | 7                            | 1                      | 6               | 0.430 |
| Cardiovascular disease      | 14                            | 3                      | 11              | 0.400 |
| Coronary artery disease     | 8                            | 2                      | 6               |      |
| Stroke                      | 5                            | 1                      | 4               |      |
| Heart failure               | 1                            | 0                      | 1               |      |
| Severe infections           | 19                            | 3                      | 16              | 0.090 |
| Pneumonia                   | 4                            | 2                      | 2               |      |
| Urinary tract infection     | 7                            | 0                      | 7               |      |
| Digestive                   | 3                            | 1                      | 2               |      |
| Cutaneous                   | 3                            | 0                      | 3               |      |
| Other                       | 2                            | 0                      | 2               |      |
| Fractures                   | 25                            | 14                     | 11              | 0.150 |

Data are number or no. (%).
*p Values were assessed by χ² test (or Fisher’s exact test).

GC, glucocorticoids.
CONCLUSIONS
This 7-year data analysis of the ESPOIR cohort did not show any significant difference in major safety events among patients with RA with and without GC treatment. These data support the good safety profile of very low-dose GC therapy in early RA. Although our findings need further confirmation, they strongly support the current recommendations that GC should be used for early RA, with DMARDs, for the shortest period and at the lowest possible dose.

Acknowledgements
The authors thank Mohamed Belakacemi for statistical advice.

Contributors
All authors participated in the conception and design of the study, contributed to the acquisition of data, participated in the analysis and interpretation of data and read, revised and approved the final manuscript. NR and JPD performed and are responsible for the statistical analyses.

Funding
CR received a grant (2838) from the French Society of Rheumatology (SFR). The Etude et Suivi des POLyaarthrites Indifférenciées Récentes (ESPOIR) cohort was supported by an unrestricted grant from Merck Sharp and Dohme for the pharmacoeconomic analysis. The ESPOIR cohort study was also supported by the French Society of Rheumatology, AbbVie, Pfizer and Roche Chugai.

Competing interests
None declared.

Ethics approval
EC Montpellier University Hospital, France.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES
22 Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open 2016;2:e000203.
Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort

Camille Roubille, Nathalie Rincheval, Maxime Dougados, René-Marc Flipo, Jean-Pierre Daurès and Bernard Combe

*Ann Rheum Dis* 2017 76: 1797-1802 originally published online February 17, 2017
doi: 10.1136/annrheumdis-2016-210135

Updated information and services can be found at:
http://ard.bmj.com/content/76/11/1797

These include:

**References**
This article cites 39 articles, 16 of which you can access for free at:
http://ard.bmj.com/content/76/11/1797#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Editor’s choice (162)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/